These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737 [TBL] [Abstract][Full Text] [Related]
4. Is there a role for partial nephrectomy in patients with metastatic renal cell carcinoma? Hellenthal NJ; Mansour AM; Hayn MH; Schwaab T Urol Oncol; 2013 Jan; 31(1):36-41. PubMed ID: 21396834 [TBL] [Abstract][Full Text] [Related]
5. Lack of retroperitoneal lymphadenopathy predicts survival of patients with metastatic renal cell carcinoma. Vasselli JR; Yang JC; Linehan WM; White DE; Rosenberg SA; Walther MM J Urol; 2001 Jul; 166(1):68-72. PubMed ID: 11435825 [TBL] [Abstract][Full Text] [Related]
6. Stage IV renal cell carcinoma. Frank W; Stuhldreher D; Saffrin R; Shott S; Guinan P J Urol; 1994 Dec; 152(6 Pt 1):1998-9. PubMed ID: 7966660 [TBL] [Abstract][Full Text] [Related]
7. Prognostic factors and the role of nephrectomy in metastatic renal cell carcinoma. Uygur MC; Usubütün A; Ozen H; Ayhan A; Kendi S J Exp Clin Cancer Res; 1999 Sep; 18(3):397-401. PubMed ID: 10606187 [TBL] [Abstract][Full Text] [Related]
8. Results of surgical treatment of renal cell carcinoma with solitary metastasis. Dineen MK; Pastore RD; Emrich LJ; Huben RP J Urol; 1988 Aug; 140(2):277-9. PubMed ID: 3398121 [TBL] [Abstract][Full Text] [Related]
10. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma. Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360 [TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. Tatokoro M; Saito K; Iimura Y; Fujii Y; Kawakami S; Kihara K J Urol; 2008 Aug; 180(2):515-9. PubMed ID: 18550105 [TBL] [Abstract][Full Text] [Related]
12. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278 [TBL] [Abstract][Full Text] [Related]
13. A Multigene Signature Based on Cell Cycle Proliferation Improves Prediction of Mortality Within 5 Yr of Radical Nephrectomy for Renal Cell Carcinoma. Morgan TM; Mehra R; Tiemeny P; Wolf JS; Wu S; Sangale Z; Brawer M; Stone S; Wu CL; Feldman AS Eur Urol; 2018 May; 73(5):763-769. PubMed ID: 29249291 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and survival of renal clear cell carcinoma patients with bone metastases. Szendroi A; Dinya E; Kardos M; Szász AM; Németh Z; Ats K; Kiss J; Antal I; Romics I; Szendroi M Pathol Oncol Res; 2010 Mar; 16(1):29-38. PubMed ID: 19639393 [TBL] [Abstract][Full Text] [Related]
15. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project). Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V; Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912 [TBL] [Abstract][Full Text] [Related]
16. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up. Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424 [TBL] [Abstract][Full Text] [Related]
17. Aggressive treatment of metastatic renal cancer. Golimbu M; Al-Askari S; Tessler A; Morales P J Urol; 1986 Oct; 136(4):805-7. PubMed ID: 3761436 [TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors for metastatic renal cell cancer]. Noguchi S; Shuin T; Kubota Y; Masuda M; Yao M; Kaneko S; Fukuda M; Senga Y; Nakahashi M; Kishida T Nihon Hinyokika Gakkai Zasshi; 1995 Jul; 86(7):1279-86. PubMed ID: 7637245 [TBL] [Abstract][Full Text] [Related]
19. Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Santoni M; Conti A; Partelli S; Porta C; Sternberg CN; Procopio G; Bracarda S; Basso U; De Giorgi U; Derosa L; Rizzo M; Ortega C; Massari F; Iacovelli R; Milella M; Di Lorenzo G; Buti S; Cerbone L; Burattini L; Montironi R; Santini D; Falconi M; Cascinu S Ann Surg Oncol; 2015; 22(6):2094-100. PubMed ID: 25472645 [TBL] [Abstract][Full Text] [Related]
20. Validation of the current prognostic models for nonmetastatic renal cell carcinoma after nephrectomy in Chinese population: a 15-year single center experience. Liu Z; Lv J; Ding K; Fu Q; Cao Q; Wang F Int J Urol; 2009 Mar; 16(3):268-73. PubMed ID: 19087209 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]